title: MDMA administration decreases serotonin but not N-acetylaspartate in the rat brain.
abstract: In animals, repeated administration of 3,4-methylenedioxymethamphetamine (MDMA) reduces markers of serotonergic activity and studies show similar serotonergic deficits in human MDMA users. Using proton-magnetic resonance spectroscopy ((1)H-MRS) at 11.7Tesla, we measured the metabolic neurochemical profile in intact, discrete tissue punches taken from prefrontal cortex, anterior striatum, and hippocampus of rats administered MDMA (5mg/kg IP, 4× q 2h) or saline and euthanized 7 days after the last injection. Monoamine content was measured with HPLC in contralateral punches from striatum and hippocampus to compare the MDMA-induced loss of 5HT innervation with constituents in the (1)H-MRS profile. When assessed 7 days after the last MDMA injection, levels of hippocampal and striatal serotonin (5HT) were significantly reduced, consistent with published animal studies. N-Acetylaspartate (NAA) levels were significantly increased in prefrontal cortex and not affected in anterior striatum or hippocampus; myo-inositol (INS) levels were increased in prefrontal cortex and hippocampus but not anterior striatum. Glutamate levels were increased in prefrontal cortex and decreased in hippocampus, while GABA levels were decreased only in hippocampus. The data suggest that NAA may not reliably reflect MDMA-induced 5HT neurotoxicity. However, the collective pattern of changes in 5HT, INS, glutamate and GABA is consistent with persistent hippocampal neuroadaptations caused by MDMA.
authors.affiliation: Department of Psychiatry and Behavioral Neurosciences, Brain Research and Imaging Neuroscience Division, Wayne State University School of Medicine, Detroit, MI 48201, USA. sperrine@med.wayne.edu
authors.forename: Shane A
authors.initials: SA
authors.lastname: Perrine
authors.forename: Farhad
authors.initials: F
authors.lastname: Ghoddoussi
authors.forename: Mark S
authors.initials: MS
authors.lastname: Michaels
authors.forename: Elisabeth M
authors.initials: EM
authors.lastname: Hyde
authors.forename: Donald M
authors.initials: DM
authors.lastname: Kuhn
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Galloway
mesh_terms: D000818:Animals; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000378:metabolism; D001921:Brain / Q000187:drug effects* / Q000378:metabolism*; D001923:Brain Chemistry / Q000187:drug effects* / Q000502:physiology; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000633:toxicity*
chemical_list: D012702:Serotonin Antagonists; D001224:Aspartic Acid; D012701:Serotonin; C000179:N-acetylaspartate; D018817:N-Methyl-3,4-methylenedioxyamphetamine
references.citation: Neuroreport. 1999 Nov 26;10(17):3675-80
references.pmid: 10619665
references.citation: Magn Reson Imaging. 1998 Oct;16(8):969-79
references.pmid: 9814780
references.citation: Ann N Y Acad Sci. 2000 Sep;914:92-103
references.pmid: 11085312
references.citation: CNS Neurol Disord Drug Targets. 2007 Apr;6(2):127-40
references.pmid: 17430150
references.citation: NMR Biomed. 2001 Jun;14(4):278-83
references.pmid: 11410946
references.citation: AJNR Am J Neuroradiol. 1999 Oct;20(9):1619-27
references.pmid: 10543631
references.citation: Crit Rev Neurobiol. 2000;14(1):23-45
references.pmid: 11253954
references.citation: Synapse. 1998 Jun;29(2):183-92
references.pmid: 9593108
references.citation: Toxicol Appl Pharmacol. 1988 Jul;94(3):448-57
references.pmid: 2456631
references.citation: Drug Saf. 1996 Aug;15(2):107-15
references.pmid: 8884162
references.citation: J Neurosci. 1988 Aug;8(8):2788-803
references.pmid: 2457659
references.citation: Brain Res. 2003 Jun 6;974(1-2):127-33
references.pmid: 12742630
references.citation: Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3127-33
references.pmid: 8475050
references.citation: Pharmacol Biochem Behav. 2008 Aug;90(2):198-207
references.pmid: 18035407
references.citation: MAGMA. 1998 Dec;7(2):95-114
references.pmid: 9951770
references.citation: Neuroscience. 2007 Mar 30;145(3):900-10
references.pmid: 17293055
references.citation: NMR Biomed. 2009 May;22(4):419-25
references.pmid: 18985626
references.citation: AJNR Am J Neuroradiol. 2002 Feb;23(2):231-7
references.pmid: 11847047
references.citation: Alcohol Clin Exp Res. 2008 Oct;32(10):1697-707
references.pmid: 18631322
references.citation: Eur Arch Psychiatry Clin Neurosci. 2001 Jun;251(3):114-6
references.pmid: 11697571
references.citation: Biosci Rep. 2007 Jun;27(1-3):69-85
references.pmid: 17510789
references.citation: J Neural Transm (Vienna). 1997;104(2-3):135-46
references.pmid: 9203077
references.citation: Pharmacol Biochem Behav. 2009 Mar;92(1):105-10
references.pmid: 19032963
references.citation: Psychol Med. 1995 Nov;25(6):1201-9
references.pmid: 8637950
references.citation: Addiction. 2005 Sep;100(9):1310-9
references.pmid: 16128720
references.citation: Neurosci Lett. 2004 May 20;362(2):113-6
references.pmid: 15193766
references.citation: J Pharmacol Exp Ther. 1987 Apr;241(1):338-45
references.pmid: 2883295
references.citation: Magn Reson Med. 1997 Jan;37(1):24-33
references.pmid: 8978629
references.citation: J Neurol Neurosurg Psychiatry. 1998 Oct;65(4):518-22
references.pmid: 9771777
references.citation: Synapse. 2002 Dec 1;46(3):199-205
references.pmid: 12325046
references.citation: Harv Rev Psychiatry. 2002 Jul-Aug;10(4):212-20
references.pmid: 12119307
references.citation: Neuropsychopharmacology. 2010 Jan;35(1):27-47
references.pmid: 19675534
references.citation: Schizophr Res. 1992 Oct;8(1):43-9
references.pmid: 1329928
references.citation: Neuropsychopharmacology. 2002 Mar;26(3):387-96
references.pmid: 11850153
references.citation: Psychopharmacology (Berl). 2001 Aug;157(1):82-8
references.pmid: 11512047
references.citation: Neurotox Res. 2001 Jan;3(1):85-99
references.pmid: 15111263
references.citation: Psychopharmacology (Berl). 2007 Jan;189(4):425-34
references.pmid: 16470404
references.citation: Neurosci Lett. 2004 Sep 9;367(3):349-54
references.pmid: 15337264
references.citation: Mitochondrion. 2008 Dec;8(5-6):396-413
references.pmid: 18590986
references.citation: J Magn Reson Imaging. 2003 Jan;17(1):11-9
references.pmid: 12500270
references.citation: Neuroscience. 2009 May 5;160(2):264-74
references.pmid: 19236907
references.citation: Neurotoxicol Teratol. 2007 Jul-Aug;29(4):466-75
references.pmid: 17466488
references.citation: J Neurosci. 1993 Mar;13(3):981-9
references.pmid: 8441018
references.citation: Ann N Y Acad Sci. 2008 Oct;1139:291-8
references.pmid: 18991874
references.citation: Annu Rev Physiol. 2003;65:401-27
references.pmid: 12524459
references.citation: Magn Reson Med. 1993 Dec;30(6):672-9
references.pmid: 8139448
references.citation: Brain Res. 1988 Apr 12;446(1):165-8
references.pmid: 2897228
references.citation: Neuroscience. 2008 Jan 24;151(2):533-43
references.pmid: 18082974
references.citation: Neuroscience. 1995 Dec;69(4):1095-1101
references.pmid: 8848098
references.citation: J Neurosci. 2001 Dec 15;21(24):9955-63
references.pmid: 11739602
references.citation: Psychopharmacology (Berl). 2007 Jan;189(4):575-6
references.pmid: 17061108
references.citation: Brain. 2008 Nov;131(Pt 11):2936-45
references.pmid: 18842607
references.citation: Psychiatry Res. 2007 Aug 15;155(3):179-88
references.pmid: 17574394
references.citation: Neuroscience. 1991;45(1):37-45
references.pmid: 1754068
references.citation: J Neuroimmune Pharmacol. 2008 Dec;3(4):203-17
references.pmid: 18709468
references.citation: J Neurol Sci. 2010 Mar 15;290(1-2):41-7
references.pmid: 20060132
references.citation: Lancet. 1998 Oct 31;352(9138):1433-7
references.pmid: 9807990
references.citation: J Pharmacol Exp Ther. 1987 Sep;242(3):911-6
references.pmid: 2443644
references.citation: Neuropsychopharmacology. 2005 Sep;30(9):1741-50
references.pmid: 15841106
references.citation: Neuropsychopharmacology. 2007 Feb;32(2):458-70
references.pmid: 17077812
references.citation: Magn Reson Med. 2009 Oct;62(4):868-79
references.pmid: 19591201
references.citation: Biol Psychiatry. 2001 Oct 1;50(7):550-4
references.pmid: 11600108
references.citation: Synapse. 2004 Sep 15;53(4):240-8
references.pmid: 15266556
references.citation: BMC Neurosci. 2008 Apr 17;9:39
references.pmid: 18419818
references.citation: Neurochem Int. 2007 Jan;50(2):386-94
references.pmid: 17074420
references.citation: Sci Pract Perspect. 2007 Apr;3(2):4-16
references.pmid: 17514067
references.citation: J Magn Reson Imaging. 1999 Oct;10(4):521-6
references.pmid: 10508318
references.citation: Cereb Cortex. 2000 Oct;10(10):974-80
references.pmid: 11007548
references.citation: Ann N Y Acad Sci. 2006 Aug;1074:365-76
references.pmid: 17105934
references.citation: Neuropsychopharmacology. 2006 Jul;31(7):1562-73
references.pmid: 16292322
references.citation: Am J Psychiatry. 2004 Jul;161(7):1181-9
references.pmid: 15229049
references.citation: Mov Disord. 2007 Feb 15;22(3):382-6
references.pmid: 17216652
references.citation: Psychopharmacol Bull. 2002 Spring;36(2):5-23
references.pmid: 12397837
references.citation: J Psychopharmacol. 2006 Mar;20(2):211-25
references.pmid: 16510479
references.citation: Pharmacol Rev. 2003 Sep;55(3):463-508
references.pmid: 12869661
references.citation: Psychopharmacology (Berl). 2007 Jan;189(4):539-56
references.pmid: 16847678